California Public Employees Retirement System Sells 38,071 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

California Public Employees Retirement System trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 23.1% in the 4th quarter, HoldingsChannel reports. The fund owned 126,386 shares of the biotechnology company’s stock after selling 38,071 shares during the quarter. California Public Employees Retirement System’s holdings in Sarepta Therapeutics were worth $12,187,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after acquiring an additional 41,465 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Sarepta Therapeutics by 1.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock worth $473,946,000 after acquiring an additional 54,698 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Sarepta Therapeutics by 40.1% during the 3rd quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company’s stock worth $97,752,000 after buying an additional 230,618 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Sarepta Therapeutics by 1.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 560,351 shares of the biotechnology company’s stock worth $67,926,000 after buying an additional 6,309 shares during the last quarter. Finally, Barclays PLC grew its stake in Sarepta Therapeutics by 29.8% during the 3rd quarter. Barclays PLC now owns 517,286 shares of the biotechnology company’s stock worth $62,705,000 after buying an additional 118,761 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SRPT has been the topic of several research analyst reports. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Barclays boosted their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. BMO Capital Markets initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They set an “outperform” rating and a $170.00 target price on the stock. Royal Bank of Canada boosted their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $128.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $156.60.

Insider Activity

In other news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 in the last quarter. 7.40% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $130.90 on Thursday. The stock has a market cap of $12.37 billion, a PE ratio of -20.88 and a beta of 0.94. The business has a 50-day simple moving average of $125.80 and a 200-day simple moving average of $110.42. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.44) EPS. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.